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Hyperammonemia, abnormalities in plasma amino 
acids and abnormalities of standard liver functions 
were corrected by orthotopic liver transplantation in a 
14-day-old boy with carbamyl phosphate synthetase-I 
deficiency and in a 35-yr-old man with argininosuccinic 
acid synthetase deficiency. The first patient had high 
plasma glutamine levels and no measure able citrulline, 
whereas citrulline values were markedly increased in 
Patient 2. Enzyme analysis of the original livers 
showed undetectable activity of carbamyl phosphate 
synthetase-I in Patient 1 and arginosuccinic acid 
synthetase in Patient 2. Both patients were comatose 
before surgery. Intellectual recovery of patient 1 has 
been slightly retarded because of a brain abscess 
caused by Aspergillus infection after surgery. Both 
patients are well at 34 and 40 mo, respectively, after 
surgery. Our experience has shown that orthotopic 
liver transplantation corrects the life-threatening 
metabolic abnormalities caused by deficiencies in the 
urea cycle enzymes carbamyl phosphate synthetase-I 
and arginosuccinic acid synthetase. Seven other 
patients-six with ornithine transcarbamylase defi-
ciency and another with carbamyl phosphate 
synthetase-I deficiency-are known to have been 
treated elsewhere with liver transplantation 1 % yr or 
longer ago. Four of these seven recipients also are well, 
with follow-ups of 1 % to 5 yr. Thus liver transplan-
tation corrects the metabolic abnormalities of three of 
the six urea cycle enzyme deficiencies, and presumably 
would correct all. (HEPATOLOGY 1992;15:419-422.) 
It was proposed in 1975 by Dr. Leon Rosenberg of Yale 
University that liver transplantation would allow so-
matic correction of diseases caused by deficiency of any 
)f the six urea cycle enzymes (Personal communication, 
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1975). The liver enzymes responsible for biosynthesis of 
urea from its principal precursors (ammonium and 
glutamine) are N-acetylglutamate synthetase, carbamyl 
phosphate synthetase-I (CPS-I), ornithine transcarba-
mylase (OTC), argininosuccinic acid synthetase (ASS), 
argininosuccinase and arginase (1). N-acetylglutamate 
synthetase deficiency has been reported in one man (2). 
OTC deficiency is an X chromosome-linked disorder, 
and the other 4 deficiencies are autosomal recessive 
traits. High plasma ammonium and glutamine levels are 
thought to cause astrocyte swelling, brain edema and 
secondary neuron injury (3), with variable neurological 
or behavioral consequences that may be acute or 
chronic. We report here the amelioration of such 
complications after liver transplantation in a 14-day-old 
white boy with CPS-I deficiency and a 35-yr-old Jap-
anese man with ASS deficiency. 
CASE REPORTS 
Case 1. An apparently normal, full-term male child of 
first-cousin parents became bradycardic and apneic shortly 
after birth on May 18, 1988, requiring endotracheal intu-
bation. By postpartum day 2, he was unresponsive to pain 
stimuli, although results of a computed tomographic scan of 
the head were normal. Serum ammonia level on day 6 was 387 
j.1mol/L, total bilirubin was 202 j.1mol/L (direct biliru-
bin = 27.4 j.1mol/L) and serum transaminases were normal. 
Peritoneal dialysis on day 7 reduced serum ammonia level from 
514 to 160 j.1mol/L. With the diagnosis of CPS-I urea cycle 
enzyme deficiency, the patient was treated with an intravenous 
infusion of arginine, sodium benzoate and sodium phenyl-
acetate supplemented with Intralipid and 5% dextrose (4), and 
tube feeding with polyxose and protein-free Mead Johnson 
formula 80056 (Mead Johnson, Evansville, IN). After transfer 
to the University of Pittsburgh, orthotopic liver transplan-
tation (OLT) was performed with a newborn cadaver liver on 
June 2, 1988, at 14 days of age. Biliary drainage was performed 
by choledochojejunostomy (Roux-en-Y anastomosis). The 
surgery and subsequent immunosuppression with cyclo-
sporine and prednisone were performed with standard tech-
niques (5). 
Severe rejection beginning in postoperative wk 3 necessi-
tated augmented steroid dosage and the addition of OKT3. An 
Aspergillus brain abscess was treated successfully with anti-
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TABLE 1. Plasma amino acids in patient 1 before and 
after OLT 
Before OLT" After OLT" 
Amino Normal As of Normal As of 
acids range 5/27/88 range 4/12/91 
Aspartic acid 1-17a 16 0-4 <10 
Glutamic acid 1-85 72 0-150 30 
Glutamine 337-673 909 320-870 650 
Proline 51-271 177 30-400 150 
Glycine 87-323 251 90-430 250 
Citrulline 10-34 ND 0-70 10 
Alpha-amino-N- 4-32 34 0-40 40 
butyric acid 
Valine 78-326 86 70-350 190 
Ornithine 22-94 59 0-120 50 
Arginine 15-115 24 10-130 30 
ND = not detectable. 
"Measured by an automated amino acid analyzer. 
bMeasured by column chromatography. 
'All data expressed as fimollL. 
TABLE 2. Plasma amino acids in patient 2 before and 
after OLT 
Amino Normal Before After 
acids range OLT (5/31/88) OLT (8/25/90) 
Aspartic acid 3.9-6.7a <3 4.5 
Glutamic acid 14-59 57 51 
Glutamine 560-890 641 612 
Proline 110-310 98 190 
Glycine 180-370 116 199 
Citrulline 22-52 445 47 
Alanine 280-650 229 424 
Valine 180-370 165 204 
Ornithine 40-100 65 124 
Arginine 70-160 207 98 
aAlI data expressed as fimollL. 












biotics, open drainage and, ultimately, ventriculoperitoneal 
shunt. Bacteremia and systemic cytomegalovirus infection 
further complicated the course, necessitating hospitalization 
for 71/2 mo (6). Subsequently, the child lived at home without 
special domiciliary care. Growth and development have been 
uninterrupted during the 40 mo of follow-up, with a weight 
gain from 2.5 to 20 kg on an unrestricted diet. Normal physical 
and intellectual milestones have been delayed, presumably 
because of the cortical injury caused by the brain abscess, 
meningitis and/or hydrocephalic complications. Liver function 
is normal, and most the recent blood ammonia level after 37 
mo was 34 fLmol/L (normal < 39 fLmol/L). 











AS = argininosuccinase. 







Case 2. A 35-yr-old Japanese man was the second son of 
healthy first-cousin parents. He had a normal brother and 
sister and was the father of a healthy daughter. He was 
ostensibly normal until three episodes of temporary altered 
consciousness and behavioral aberrations occurred in January, 
April and May 1987. After initial psychiatric hospitalization, 
he was transferred to Kurume University, where his serum 
ammonium and serum citrulline levels were 264 and 445 
fLmol/L, respectively (normal, < 39 and < 52 fLmollL). On 
diagnosis of ASS deficiency, he was prescribed sodium ben-
zoate, arginine and branched amino acid infusion, with 
restriction of oral protein intake. During the following 18 mo, 
he had four major episodes of serum ammonium elevation, 
with transient bouts of stage IV coma, which were successfully 
treated by hemodialysis. Because of deterioration and stage III 
and IV coma necessitating ventilator support, he was flown in 
November 1988 to the University of Pittsburgh, where OLT 
was performed on December 23,1987, with biliary drainage by 
duct-to-duct anastomosis. 
Preoperative total serum bilirubin of 425 fLmoliL fell to 
normal within a few days. A computed tomographic scan of the 
head in November 1988 had revealed cortical atrophy. Post-
operatively, complete recovery of consciousness and removal 
from ventilator support required several weeks, but convales-
cence was otherwise uncomplicated under cyclosporine-steroid 
therapy (5). The patient was discharged from the hospital after 
44 days and has been at home since then. Recovery of 
neuromotor and intellectual capabilities required many 
months, but eventually the patient returned to his previous 
position as vice president of a construction company. Liver 
function is normal 34 mo postoperatively. Blood ammonia 
levels have been 7 to 21 fLmollL (normal < 39 j.1mol/L). 
BIOCHEMICAL METHODS 
Amino Acids. Plasma amino acids in patient 1 were 
measured 9 days after birth (5 days before transplan-
tation) by an automated amino acid analyzer. At 34 mo 
after OLT, amino acids were determined by column 
chromatography (7). Amino acid separation was per-
formed by a method modified from Hamilton (8). In 
Patient 2, the plasma amino acids were measured in the 
absence of treatment, 5 to 7 rna before transplantation, 
with a automated amino acid analyzer. The examina-
tions were repeated 3, 4, and 20 mo after OLT. 
Liver Enzymes. The removed native livers were im-
mediately cut into small pieces, frozen with liquid 
nitrogen and stored at - 800 C until the analyses of urea 
cycle enzymes. CPS-I and OTC were measured in 
Patient 1 in the Department of Human Genetics of the 
Yale University School of Medicine. Determinations 
were with a small-scale adaptation of the method of 
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TABLE 5. Urea cycle enzyme deficiencies treated more than }l/2 yr ago with OLT 
OUTCOME 
Date of Age at Enzyme 
Patient Center OLT OLT deficiency Alive/dead Mental state Reference 
1 Yale University 8/86 21mo OTC Alive Normal and 1; personal com-
in school munication of 
8/91a 
2 Lille, France 2/88 5yr OTC Alive Normal 13; personal com-
munication of 
8/91 
3 University of Pittsburgh 6/88 14 days CPS-I Alive Slightly re- This report 
tarded 
4 Boston Children's Hospital 8/88 18mo OTC Alive Normal Personal communi-
cation of 8/91 
5 University of Minnesota 10/88 20mo CPS-I Died of pneumonia 14 
6 University of Pittsburgh 12/88 35yr 
7 University of Chicago 10/89b 20mo 
8 University of Chicago 11/89 21 mo 
9 Riley Children's Hospital, 2/90 28mo 
Indianapolis, IN 
uDr. Wayne Flye of Washington University, St. Louis, MO. 
bLiver fragment. 
Nuzum and Snodgrass (9). The liver tissues from 
Patient 2 were analyzed for CPS-I, OTC, ASS and AS 
activity in the Department of Biochemistry of Ka-
goshima University, Kagoshima, Japan, using a previ-
ously described method (10). 
RESULTS 
Plasma Amino Acids. The pretransplant plasma in 
Patient 1 had elevated levels of glutamine. Citrulline 
was undetectable, and the other measured amino acids 
were relatively normal (Table 1). Plasma amino acids 34 
mo after surgery were normal. Citrulline levels became 
detectable. 
The plasma amino acids in Patient 2 before and after 
transplantation are summarized in Table 2. The ex-
tremely high preoperative levels of citrulline and the 
modest elevations of arginine were corrected at all 
measured postoperative times. However, ornithine level 
(normal = 40 to 100 J.Lmol/L) was slightly elevated at 3 
mo (153 J.Lmol!L) and at 20 mo (124 J.LmoI/L) postoper-
atively. 
Tissue Studies. On light microscopy, the native liver of 
patient 1 had only minor, nonspecific abnormalities. 
Similarly, electron microscopic studies were normal, 
except for nonspecific elongation of the mitochondria. 
CPS-I activity was undetectable in the homogenate of 
this liver. OTC activity was normal when compared with 
that of a control liver sample (Table 3). 
The native liver of patient 2 was enlarged, with 
cholestasis and massive steatosis and hemosiderosis. 
Periportal fibrosis, but no cirrhosis, was present. The 
liver homogenate was devoid of ASS activity, but 
exhibited significant CPS-I, OTC, and AS activity 
(Table 4). 
after 18 mo 
ASS Alive Normal This report 
OTC Died 5/26/90 12 
OTC Died 11/17/89 Personal communi-
cation of 4/91 
OTC Alive Retarded Personal communi-
cation of 8/91 
DISCUSSION 
The diagnosis of urea cycle enzyme deficiency and the 
specific enzyme involved were established with certainty 
in our two cases. Both had hyperammonemia and 
plasma amino acid abnormalities, which permitted the 
presumptive diagnosis of the enzyme deficiency. The 
diagnoses were confirmed by analysis of the subse-
quently excised livers. To our knowledge, the 2-wk-old 
infant with CPS-I deficiency is the youngest patient ever 
to undergo successful liver transplantation. The 36-
yr-old man is the only patient with ASS deficiency 
treated thus far with liver transplantation. Although 
both patients were comatose at the time of liver 
replacement, their lethal metabolic abnormalities were 
promptly and permanently corrected; this has been 
achieved with numerous other liver-based inborn errors 
(11). 
In addition to these two patients, seven others with 
urea cycle deficiencies are known to have been treated 
with liver transplantation before March 1990 (Table 5). 
Six of the seven had OTC deficiency (12, 13). The 
seventh was a 20-mo-old boy with CPS-I deficiency (14). 
Postoperatively, this child had undetectable citrulline in 
the plasma, prompting Tuchman to recommend cit-
rulline supplementation postoperatively (14). This 
treatment was not provided in our patient with CPS-I 
deficiency during his more-than-3-yr survival. The 
finding of citrulline in the plasma of our patient suggests 
that in the human, unlike the rat (15, 16), citrulline 
originates in the liver and in the gut. It is also 
noteworthy that the amino acid profile was not com-
pletely corrected by liver transplantation in Patient 2. 
Plasma ornithine level remained slightly high as late as 
20 mo after surgery. 
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The cumulative experience in our two cases and in the 
seven others elsewhere establishes the effectiveness of 
liver transplantation for at least three urea cycle 
deficiencies. When the operation is successful, the 
metabolic consequences are corrected to an extent not 
approached by attempts to activate alternative pathways 
of waste nitrogen synthesis and excretion or by re-
striction of dietary protein intake. However, the use of 
liver transplantation for somatic correction may prove to 
be only a step toward enzyme replacement. Such therapy 
with measures other than whole-liver or even isolated 
hepatocyte transplantation is not hard to envision with 
recent advances in understanding of the molecular basis 
for these diseases. Virus-mediated transfer of human 
ASS has already been accomplished in rodents (17, 18), 
suggesting that the introduction of a functional comple-
mentary DNA into hepatic or nonhepatic autologous 
cells could be a practical therapeutic possibility in the 
near future. 
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